InsidersTradesSigma
PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 Stock: price and directors' dealings · Italy · Consob
CONSOB:pharmanutra-pharmanutra-spa-cda-approva-il-resoconto-intermedio-di-gestione-al-3IT·ConsobMcap €861.8MHealth Care
Follow the PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 share price and the full directors' dealings record of the company, a publicly traded company based in Italy. Shares are quoted on IT IT, under the authority of Consob. Operating in the Health Care sector, PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 has published 1 insider filings. Market capitalisation: €861.8m. The latest transaction was disclosed on 10 November 2025 (Other). Among the most active insiders: Unknown. All data is accessible without an account.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025 Strong Buy (bullish), based on 3 analysts. Average price target: €81.33.
Fundamental score
Ranked 7,946 of 26,212 companies
61.3
score / 100
Value37
Quality85
FCF yld1.9%
Earn yld2.3%
EV/EBITDA25.7x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 November 2025